Bristol Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Squibb announced that its Board of Directors has declared a quarterly dividend of 62c per share on the 10c par value common ...

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with ...

This was the stock's third consecutive day of losses.

Given its better prospects, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). BMY stock trades at 8.3x its ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $59.38 which represents a slight increase of $0.54 or 0.92% from the prior close of $58.84. The stock opened at $58.84 and ...

Accent Therapeutics appoints Serena Silver as chief scientific officer as it advances Phase I/II ATX-559 trials for advanced ...

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Multi-Factor Investor model based on the published ...

Shares of Bristol Myers Squibb Co. BMY slid 1.00% to $58.12 Tuesday, on what proved to be an all-around grim trading session ...

If we earn a $0.63 per share dividend in early January, and then if BMY closes above $60 on January 17, we would be assigned ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $59.27 which represents a slight increase of $0.53 or 0.90% from the prior close of $58.74. The stock opened at $58.82 and ...